ArticleThoracic cancer2019
Prognostic value of pretreatment inflammatory biomarkers in primary small cell carcinoma of the esophagus.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Survival analysis of small cell carcinoma of the esophagus: a 15-year retrospective study from a high-incidence region.Journal of gastrointestinal oncology · 2025Article
- Primary Esophageal Small Cell Neuroendocrine Carcinoma: A Case Report With a Review of Presentation, Treatment, and Survival.Clinical case reports · 2025Article
- Development and validation of a prognostic model for overall survival in small cell carcinoma of the esophagus.Frontiers in oncology · 2025Article
- Primary small cell esophageal carcinoma, chemotherapy sequential immunotherapy: A case report.World journal of clinical cases · 2021Article
- Prognostic value of biomarkers in primary small cell carcinoma of the esophagus.Thoracic cancer · 2020Article
- Primary small cell carcinoma of the esophagus: progression in the last decade.Annals of translational medicine · 2020Review
- Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment.In vivo (Athens, Greece)Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence indicates that several inflammatory biomarkers may predict survival in patients with malignant tumors. The aim of this study was to evaluate the prognostic value of pretreatment biomarkers in patients with primary small-cell carcinoma of the esophagus (PSCCE).
methodsA total of 73 PSCCE patients enrolled between January 2009 and December 2017 at the Affiliated Cancer Hospital of Zhengzhou University. The total lymphocyte counts (TLC), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) prior to anticancer therapy were collected as inflammation biomarkers. The cutoff value was determined by Receiver operating characteristic (ROC). The Kaplan-Meier method was utilized to analyze overall survival (OS). Cox proportional hazards regression was used to identify univariate and multivariate prognostic factors.
resultsUnivariate analysis showed that high NLR group (hazard ratio [HR] = 1.685; 95% CI: 1.001-2.838; P = 0.047) and high PLR group (hazard ratio [HR] = 1.716; 95% CI: 1.039-2.834; P = 0.033) were associated with poor OS, and TLC was not correlated with OS. On multivariate analysis, high PLR (hazard ratio [HR] = 1.751; 95% CI: 1.042-2.945; P = 0.035) was an independent prognostic factor of unfavorable OS.
conclusionsPretreatment PLR and NLR are correlated with OS. These biomarkers are easily accessible, cost effective, and can serve as a marker to identify high-risk patients for further designing personalized treatment and predicting treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.